SCHEMBL20033792

SCHEMBL20033792

CCOC(=O)CC(C)c1cncnc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.41
GAA P10253 1/20 0.41
SI P14410 1/20 0.41
MGAM2 Q2M2H8 1/20 0.41
ALDH1A1 P00352 5/20 0.38
KDM4E B2RXH2 3/20 0.38
HTT P42858 1/20 0.38
SIRT2 Q8IXJ6 1/20 0.37
TSHR P16473 1/20 0.37
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
GABRA1 P14867 2/20 0.36
GABRB2 P47870 2/20 0.36
CYP11B1 P15538 2/20 0.36
CYP11B2 P19099 2/20 0.36
LMNA P02545 2/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
ABCB11 O95342 1/20 0.36
GABRA2 P47869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20033794 0.83 ALDH1A1 (0.38) MGAMGAASIMGAM2ALDH1A1
SCHEMBL6981185 0.82 ALDH1A1 (0.40) MGAMGAASIMGAM2ALDH1A1
SCHEMBL20154360 0.82 ALDH1A1 (0.40) MGAMGAASIMGAM2ALDH1A1
SCHEMBL2370448 0.81 L3MBTL1 (0.47) GAATSHRLMNASMN1; SMN2MAPT
SCHEMBL19669373 0.81 GAA (0.38) MGAMGAASIMGAM2ALDH1A1
SCHEMBL2370246 0.80 NAMPT (0.45) MGAMGAASIMGAM2ALDH1A1
SCHEMBL19669372 0.78 CYP1A2 (0.37) MGAMGAASIMGAM2ALDH1A1
SCHEMBL14567313 0.77 HPGD (0.48) GAAALDH1A1HTTCYP1A2CYP3A4
SCHEMBL13318231 0.76 CA12 (0.42) ALDH1A1KDM4EHTTTSHRCYP1A2
SCHEMBL23027267 0.76 LTB4R (0.54) ALDH1A1KDM4ETSHRCYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220218702-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER BIO-PHARM SOLUTIONS CO., LTD. (KR) 2022-07-14 US disclosed
US-9937145-B2 Sulfamate derivative compound for use in preventing or treating epilepsy BIO-PHARM SOLUTIONS CO., LTD. (KR) 2018-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220218702-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER SLC6A4, SLC6A3, SLC6A2 MGAM 1110/4885GAA 640/4885SI 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.